KR100221118B1 - 겸상 적혈구 질환을 치료하기 위한 정분자적 방법 - Google Patents

겸상 적혈구 질환을 치료하기 위한 정분자적 방법 Download PDF

Info

Publication number
KR100221118B1
KR100221118B1 KR1019930702363A KR930702363A KR100221118B1 KR 100221118 B1 KR100221118 B1 KR 100221118B1 KR 1019930702363 A KR1019930702363 A KR 1019930702363A KR 930702363 A KR930702363 A KR 930702363A KR 100221118 B1 KR100221118 B1 KR 100221118B1
Authority
KR
South Korea
Prior art keywords
vitamin
pharmaceutical composition
group
weight
sickle cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019930702363A
Other languages
English (en)
Korean (ko)
Inventor
마이클 윌번
Original Assignee
윌번, 마이클
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌번, 마이클 filed Critical 윌번, 마이클
Application granted granted Critical
Publication of KR100221118B1 publication Critical patent/KR100221118B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1019930702363A 1991-02-08 1992-01-31 겸상 적혈구 질환을 치료하기 위한 정분자적 방법 Expired - Fee Related KR100221118B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US652.773 1991-02-08
US07/652,773 US5108754A (en) 1991-02-08 1991-02-08 Orthomolecular method of treating sickle cell disease
PCT/US1992/000450 WO1992013522A1 (en) 1991-02-08 1992-01-31 Orthomolecular method of treating sickle cell disease

Publications (1)

Publication Number Publication Date
KR100221118B1 true KR100221118B1 (ko) 1999-09-15

Family

ID=24618098

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930702363A Expired - Fee Related KR100221118B1 (ko) 1991-02-08 1992-01-31 겸상 적혈구 질환을 치료하기 위한 정분자적 방법

Country Status (15)

Country Link
US (1) US5108754A (enExample)
EP (1) EP0571474B1 (enExample)
JP (1) JPH06507382A (enExample)
KR (1) KR100221118B1 (enExample)
AP (1) AP275A (enExample)
AT (1) ATE175204T1 (enExample)
AU (1) AU662124B2 (enExample)
BR (1) BR9205609A (enExample)
CA (1) CA2103580C (enExample)
DE (1) DE69228054T2 (enExample)
DK (1) DK0571474T3 (enExample)
ES (1) ES2125887T3 (enExample)
GR (1) GR3029742T3 (enExample)
IL (1) IL100663A (enExample)
WO (1) WO1992013522A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190092778A (ko) 2018-01-31 2019-08-08 양원용 태양광을 이용한 기능성 전동식 농약분무기

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
HUT72422A (en) * 1994-04-20 1996-04-29 Beres Export Import Rt Aquous concentrate and process for its preparation
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
DE10062401A1 (de) * 2000-12-14 2002-06-20 Beiersdorf Ag Verwendung von Folsäure und/oder deren Derivaten zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe von Schäden an der hauteigenen DNA und/oder zur Reparatur bereits eingetretener Schäden an der hauteigenen DNA
KR20020088498A (ko) * 2001-05-17 2002-11-29 (주)미토콘 에스-아데노실메티오닌을 유효성분으로 함유하는 인슐린저항증 개선용 조성물
DE10243234A1 (de) * 2002-09-17 2004-03-25 Phenion Gmbh & Co. Kg Tocopherylester
AU2004257693B8 (en) 2003-07-09 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US7250445B1 (en) * 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
JP2011507968A (ja) * 2007-12-27 2011-03-10 エイヤーズ ファーマシューティカルズ、インク． エアロゾル化ニトライトおよび一酸化窒素供与性化合物ならびにそれらの使用
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
US20170227495A1 (en) * 2014-07-30 2017-08-10 Case Western Reserve University Biochips to diagnose hemoglobin disorders and monitor blood cells
JP2017530976A (ja) * 2014-10-08 2017-10-19 エピジェネティクス・ファーマ・エルエルシー ビタミンｅ−ヌクレオシド・プロドラッグ
WO2016196281A1 (en) * 2015-06-01 2016-12-08 Nanometics Llc Mtap inhibitors for the treatment of sickle cemtap disease
US10349589B2 (en) 2016-09-08 2019-07-16 Hemex Health, Inc. Diagnostics systems and methods
CN109923417B (zh) 2016-09-08 2021-06-08 希米斯保健股份有限公司 诊断系统和方法
US11740203B2 (en) 2019-06-25 2023-08-29 Hemex Health, Inc. Diagnostics systems and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL57609A (en) * 1979-06-21 1983-05-15 Yeda Res & Dev Pharmaceutical compositions for the treatment of sickle cell disease comprising p-nitrobenzyl esters or amides of aromatic or hydrophobic aminoacids
US4612194A (en) * 1984-02-15 1986-09-16 Roshdy Ismail Anti-rheumatic agents and their use
GB8606913D0 (en) * 1986-03-20 1986-04-23 Hider R C Treatment of sickle cell disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190092778A (ko) 2018-01-31 2019-08-08 양원용 태양광을 이용한 기능성 전동식 농약분무기

Also Published As

Publication number Publication date
WO1992013522A1 (en) 1992-08-20
GR3029742T3 (en) 1999-06-30
CA2103580A1 (en) 1992-08-09
EP0571474B1 (en) 1998-12-30
US5108754A (en) 1992-04-28
ATE175204T1 (de) 1999-01-15
DE69228054D1 (de) 1999-02-11
DE69228054T2 (de) 1999-08-05
AU662124B2 (en) 1995-08-24
ES2125887T3 (es) 1999-03-16
AP9200358A0 (en) 1992-04-30
EP0571474A1 (en) 1993-12-01
AP275A (en) 1993-07-18
BR9205609A (pt) 1994-07-26
JPH06507382A (ja) 1994-08-25
DK0571474T3 (da) 1999-08-30
IL100663A0 (en) 1992-09-06
EP0571474A4 (enExample) 1994-02-09
AU1250592A (en) 1992-09-07
CA2103580C (en) 2002-11-26
IL100663A (en) 1995-10-31

Similar Documents

Publication Publication Date Title
KR100221118B1 (ko) 겸상 적혈구 질환을 치료하기 위한 정분자적 방법
Abraham et al. Vanillin, a potential agent for the treatment of sickle cell anemia
Rieder et al. Hemoglobin Zürich: clinical, chemical and kinetic studies
JPH0534337B2 (enExample)
Crawhall et al. Cystinosis: Plasma cystine and cysteine concentrations and the effect of D-penicillamine and dietary treatment
Childs et al. Further observations of a patient with hyperglycinemia
US5177208A (en) Orthomolecular method of treating sickle cell disease
KOGUT et al. Tyrosinosis
Savage et al. Idiopathic rhabdomyolysis
Furia et al. The effect of aspirin on sickling and oxygen affinity of erythrocytes
JP2529605B2 (ja) 免疫賦活剤
Danks et al. A new form of prolonged transient tyrosinemia presenting with severe metabolic acidosis
KR20040106367A (ko) 디프룩토오스 무수물 함유 조성물 및 그의 용도
JP2024533530A (ja) 複合ジンセノシド組成物を含む抗炎症組成物
RU2107511C1 (ru) Стабилизированная фармацевтическая композиция на основе рекомбинантного негликозилированного интерлейкина человека в восстановленном виде il-2 и способ ее получения
Charache et al. Hemoglobin SC, SS/GPhiladelphia and SOArab diseases: Diagnostic importance of an integrative analysis of clinical, hematologic and electrophoretic findings
Pennell et al. Preparation of stabilized solutions of hemoglobin
JP2024110378A (ja) 腎機能障害を予防または治療するための組成物の製造におけるペディオコッカス・アシディラクティシｇｋａ４の使用
EP0306377A1 (fr) Nouvelles compositions d'éléments minéraux et/ou oligoéléments et leur procédé de préparation
ABEL et al. Pathophysiology of the hemoglobinopathies
JPH06321778A (ja) ３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤
Silvis et al. Treatment of severe liver failure with hyperalimentation.
Waslien et al. Folate requirements of children. I. A formula diet low in folic acid for study of folate deficiency in protein–calorie malnutrition
EP3231296A1 (en) Use of a composition comprising alpha-lipoic acid
Shastri Kinetics of sulphafurazole in undernutrition.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20020620

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030626

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030626